SCHEMBL211307

SCHEMBL211307

Cc1nc2[c]cccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
PARP1 P09874 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
RAB9A P51151 3/20 0.36
POLB P06746 2/20 0.36
NPC1 O15118 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSP90AA1 P07900 1/20 0.32
ESR2 Q92731 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HTT P42858 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HSD17B10 Q99714 1/20 0.31
DHODH Q02127 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16095983 0.77
SCHEMBL5525401 0.76
SCHEMBL3499660 0.76 NUDT1 (0.48) ALDH1A1MEN1KMT2A
SCHEMBL8470141 0.76
SCHEMBL7021216 0.76 DDAH1 (0.53) ALDH1A1SMN1; SMN2POLBHPGDKDM4E
SCHEMBL7017594 0.76 KDM4E (0.32) ALDH1A1SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL7257015 0.76 L3MBTL1 (0.36) ALDH1A1PARP1SMN1; SMN2KDM4EGAA
SCHEMBL7014749 0.76 LMNA (0.33) ALDH1A1RAB9ANPC1MEN1KMT2A
SCHEMBL16321762 0.74 PARP1 (0.54) ALDH1A1PARP1SMN1; SMN2RAB9ANPC1
SCHEMBL7024978 0.73 DDAH1 (0.39) SMN1; SMN2RAB9APOLBNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2022-05-03 US claimed
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2021-08-05 US claimed
CN-111434658-A Organic electroluminescent materials and devices 机光科技股份有限公司 2020-07-21 CN claimed
EP-3256462-A1 SUBSTITUTED 2-THIOIMIDAZOLYL-CARBOXAMIDES AS PEST CONTROL AGENTS Bayer CropScience Aktiengesellschaft (DE) 2017-12-20 EP claimed
WO-2016128298-A1 SUBSTITUTED 2-THIOIMIDAZOLYL-CARBOXAMIDES AS PEST CONTROL AGENTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-08-18 WO claimed
EP-2969593-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC IMINES Bridgestone Corporation (JP) 2016-01-20 EP claimed
WO-2014149931-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC IMINES BRIDGESTONE CORPORATION (JP) 2014-09-25 WO claimed
EP-0034116-A2 N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1981-08-19 EP claimed
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents SERINA THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2024-03-12 US disclosed
WO-2023178017-A1 DEACYLATION OF CARBOHYDRATE COMPOUNDS ELYSIUM HEALTH INC. (US) 2023-09-21 WO disclosed
CN-111743901-B Spray-dried formulations 普尔莫凯恩股份有限公司 2023-09-12 CN disclosed
EP-3054937-B1 SPRAY DRY FORMULATIONS PULMOKINE INC (US) 2023-07-26 EP disclosed
US-11692090-B2 Dielectric cross-linked fluoropolymer DAIKIN AMERICA, INC. (US) 2023-07-04 US disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
EP-0280951-A1 Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates Roche Diagnostics GmbH (DE) 1988-09-07 EP disclosed
EP-0120589-B1 IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP disclosed
EP-0200915-A1 Aminopropanol derivatives, process for their preparation, their use and medicines containing them Roche Diagnostics GmbH (DE) 1986-11-12 EP disclosed
US-4621084-A CARDIOTONIC, ANTIULCER FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-11-04 US disclosed
EP-0120589-A1 Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents CD44, CD47, LNPEP ALDH1A1 2919/4885PARP1 537/4885SMN1; SMN2 580/4885
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A ALDH1A1 2880/4885PARP1 3206/4885SMN1; SMN2 2544/4885
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same ERBB3, ERBB2, PANK2 ALDH1A1 3859/4885PARP1 275/4885SMN1; SMN2 2101/4885
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 ALDH1A1 2885/4885PARP1 3709/4885SMN1; SMN2 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.